Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS).

A higher proportion of patients with a best overall systemic response of SD and PD in the aumolertinib arm showed an increasing trend in CNS target lesions (Supplementary Figure S1 ).

also in 63,971 other papers

Concordance between CNS response and systemic response By grouping the patients according to the best overall systemic response, we found that most patients with a best overall systemic response of CR and PR showed a decreasing trend in CNS target lesions.

also in 47,180 other papers